Preparation method and application of hybrid nanogel for strengthening tumor sonodynamic therapy

A hybrid nanogel with a hydrophilic polymer derivative and nano manganese dioxide encapsulates hypoxia-responsive drugs, addressing sonosensitizer aggregation and hypoxic targeting to enhance sonodynamic therapy efficacy.

CN119074920AActive Publication Date: 2024-12-06HEBEI UNIV OF TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411223056.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-12-06
Estimated Expiration
2044-09-03

AI Technical Summary

Technical Problem

Existing sonodynamic therapies face challenges due to hydrophobicity-induced aggregation of sonosensitizers, reducing efficiency, and the inability to effectively target hypoxic tumor regions, which limits therapeutic effectiveness.

Method used

A hybrid nanogel is prepared using a hydrophilic polymer derivative modified with phenylboronic acid and a sonosensitizer, self-assembled with nano manganese dioxide, encapsulating hypoxia-responsive drugs to enhance sonodynamic therapy by targeting hypoxic tumor sites.

Benefits of technology

The nanogel achieves high sonodynamic therapy efficiency by inhibiting tumor energy metabolism and selectively activating drugs at hypoxic sites, enhancing treatment efficacy under both normoxic and hypoxic conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074920A_ABST
    Figure CN119074920A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method of a hybrid nanogel for strengthening tumor sonodynamic therapy. The preparation method comprises the following steps: self-assembling a hydrophilic polymer derivative in manganese dioxide in an inorganic salt solution to encapsulate a hypoxia response type drug; the hydrophilic polymer derivative is obtained by modifying phenylboronic acid and a sound-sensitive agent on a hydrophilic polymer material through a one-step method; the hydrophilic polymer material is selected from any one of starch, dextrin, hyaluronic acid, chitosan, glucan, gelatin or silk fibroin. Hydrophilic polymer derivatives are constructed through one-step modification, the hydrophilic polymer derivatives and manganese dioxide nano-particles are self-assembled into hybrid nanogel, the efficient sonodynamic therapy effect and inhibition on self energy metabolism of tumor parts are achieved, hypoxia response drugs entrapped by the nanogel can be specifically activated at the tumor hypoxia parts, and the hypoxia response drugs can be used for treating tumor hypoxia. And a synergistic tumor sonodynamic treatment effect is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a method for preparing a nanogel and application thereof, and in particular to a method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy and application thereof. Background Art

[0002] Sonodynamic therapy has the advantages of high temporal and spatial accuracy, minimal invasiveness, and low systemic toxicity, and is widely used in the treatment of malignant tumors. During the photodynamic process, external laser irradiation can activate photosensitizers in the tumor site to produce reactive oxygen species, which upregulates intracellular oxidative stress. Due to problems such as the hydrophobicity of traditional sonosensitizers, various carriers are required to encapsulate them for in vivo delivery. However, traditional sonosensitizers will aggregate in the hydrophobic regions of the carriers, causing aggregation quenching and reducing the sonodynamic efficiency. In addition, there is still a lack of effective methods for ultrasound therapy of hypoxic segments of tumors with insufficient oxygen supply. In order to improve the sonodynamic efficiency, it is particularly important to optimize the sonodynamic tumor treatment strategy based on traditional sonosensitizers.

[0003] Compared with normal cells, tumor cells show various abnormal physiological indicators, which also makes it possible to treat tumors by regulating tumor cell metabolism. The concentrations of glutathione and adenosine triphosphate in tumor cells are higher than those in normal cells. At the same time, due to abnormal vascular distribution and insufficient nutrient supply, hypoxic areas exist in tumors. The abnormal physiological characteristics of tumors also greatly reduce the effectiveness of single treatment methods. For example, the high level of reactive oxygen species induced by the sonodynamic process can effectively kill tumors, while the high concentration of glutathione in tumor cells will neutralize the reactive oxygen species and reduce the killing effect of tumors. In addition, a large part of the hypoxic microenvironment of tumors is caused by the vigorous self-consumption of tumors, and its oxygen consumption also limits the therapeutic effect of sonodynamics. In addition, the hypoxic microenvironment will also weaken the killing effect of amplified oxidative stress on tumors.

[0004] By using starvation therapy to achieve glucose consumption in the tumor site, the tumor's own metabolism can be reduced, thereby enhancing the effect of sonodynamic therapy. In addition, adenosine triphosphate (ATP) has attracted our attention as the most direct energy source for the human body. The ATP-based energy supply mechanism of tumor cells is a restricted process that requires rapid conversion between ATP and adenosine diphosphate (ADP). Therefore, limiting the free conversion between ATP and ADP in the tumor site may be an effective energy blocking strategy, which can enhance the therapeutic effect of sonodynamic therapy by reducing the tumor's own endogenous oxygen consumption. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a method for preparing hybrid nanogel for enhancing tumor sonodynamic therapy.

[0006] The technical solution of the present invention to solve the above technical problems is as follows: a method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy, using a hydrophilic polymer derivative to self-assemble in manganese dioxide in an inorganic salt solution to encapsulate hypoxia-responsive drugs; the hydrophilic polymer derivative is obtained by modifying phenylboronic acid and a sonosensitizer on a hydrophilic polymer material through a one-step method; the hydrophilic polymer material is selected from any one of starch, dextrin, hyaluronic acid, chitosan, dextran, gelatin or silk fibroin.

[0007] The beneficial effects of the present invention are as follows: the present invention constructs a hydrophilic polymer derivative through a one-step modification, and independently assembles it into a hybrid nanogel with nano manganese dioxide, thereby achieving a highly efficient sonodynamic therapy effect and inhibiting the energy metabolism of the tumor site itself; the hypoxia-responsive drug encapsulated in the nanogel can be specifically activated at the hypoxic site of the tumor, thereby achieving a synergistic tumor sonodynamic therapy effect.

[0008] The present invention uses manganese dioxide to aggregate and precipitate in inorganic salts. With the assistance of inorganic salts, manganese dioxide can be directionally encapsulated and self-assembled into the hydrophilic polymer material to form a nanogel. The nanogel obtained by the directional encapsulation and self-assembly has stable performance.

[0009] Based on the above technical solution, the present invention can also be improved as follows.

[0010] Furthermore, the molecular weight of the hydrophilic polymer material is 10000-200000; the degree of substitution of the sonosensitizer on the main chain of the hydrophilic polymer material is 20-50 μg / mg, preferably, the degree of substitution is 40 μg / mg; the degree of substitution of phenylboric acid on the main chain of the hydrophilic polymer material is 20-200 μg / mg.

[0011] The beneficial effects of adopting the above further scheme are: since the sonosensitizer will produce aggregation quenching, the present invention reduces its aggregation quenching by controlling the modification ratio of the sonosensitizer on the dextrin polymer to make it in a loose state. The sonosensitizer modification greater than 50 μg / mg will produce aggregation quenching, which significantly affects the sonodynamic efficiency; the sonosensitizer with a substitution degree lower than 20 ug / mg cannot provide an effective hydrophobic area on the hydrophilic polymer material and cannot form a hybrid nanogel;

[0012] The present invention uses phenylboronic acid and sonosensitizer to modify the hydrophilic polymer material through a one-step method, thereby enabling the phenylboronic acid exposed on the surface of the hydrogel to bind to the sialic acid receptors overexpressed on the surface of tumor cells, thereby playing a tumor targeting role. The internal phenylboronic acid can bind to ATP in the tumor cells, reduce the energy metabolism of the tumor cells themselves, and provide more oxygen for the sonosensitizer.

[0013] Furthermore, the polymer hydrophilic polymer material is dextrin; the sonosensitizer is protoporphyrin IX, and the phenylboric acid is 4-carboxyphenylboric acid.

[0014] Furthermore, the inorganic salt solution is sodium dihydrogen phosphate and disodium hydrogen phosphate solution; the surface of the manganese dioxide is modified with any one of polyallylamine, polyethyleneimine or chitosan; and the phenylboric acid is any one of 4-aminophenylboric acid, 3-aminophenylboric acid, o-aminophenylboric acid, 4-carboxyphenylboric acid, 3-carboxyphenylboric acid or 2-carboxyphenylboric acid.

[0015] Furthermore, the surface-modified manganese dioxide has a positive potential and a size of 10-40 nanometers.

[0016] Furthermore, the hypoxia-responsive drug is one of tirapazamine, apaziquinone, ivophosphamide, banothramine and tasotinib.

[0017] Furthermore, the phenylboric acid and sonosensitizer are modified on a hydrophilic polymer material by a one-step method, specifically: the hydrophilic polymer material is dissolved in a dimethyl sulfoxide solvent, and then dicyclohexylcarbodiimide and 4-dimethylaminopyridine are added to obtain a hydrophilic polymer material solution, the mixture of phenylboric acid and sonosensitizer is stirred at 40-55° C. under nitrogen protection to obtain a mixed solution, preferably 50° C., the mixed solution is added to ice-cold ether, centrifuged, and a white precipitate is obtained and dissolved in deionized water, dialyzed using a dialysis bag, and freeze-dried.

[0018] Furthermore, the molecular weight of the selected dialysis bag is 10,000 to 100,000 molecular weight, and the concentration of the dialysate is 0.01 molar.

[0019] Furthermore, the mass ratio of the hydrophilic polymer material to manganese dioxide is 100:0.5-10, preferably 100:1-6, and the concentration of the hypoxia-responsive drug is 100 μg / mL.

[0020] The present invention also provides an application of the hybrid nanogel obtained by the above method for preparing the hybrid nanogel for enhancing tumor sonodynamic therapy in preparing therapeutic drugs for tumors or hypoxic tumor-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 It is the nuclear magnetic resonance hydrogen spectrum of the hydrophilic polymer derivative dextrin-protoporphyrin IX-phenylboronic acid (Dex-PpIX-PBA) in the present invention.

[0022] Figure 2 It is the infrared spectrum of the hydrophilic polymer derivative dextrin-protoporphyrin IX-phenylboronic acid (Dex-PpIX-PBA) in the present invention.

[0023] Figure 3It is the ultraviolet absorption peak of protoporphyrin IX of different concentrations in the present invention and its concentration-ultraviolet absorbance standard curve at 406nm.

[0024] Figure 4 It is the ultraviolet absorption peak of phenylboric acid of different concentrations in the present invention and its concentration-ultraviolet absorbance standard curve at 252nm.

[0025] Figure 5 The singlet oxygen generation of Dex-PpIX-PBA with different protoporphyrin IX substitution degrees prepared in the present invention.

[0026] Figure 6 The particle size distribution diagram and transmission electron microscopy (scale bar = 200 nm) of the hybrid nanogel (DPP / TPZ@MnO2) prepared in the present invention.

[0027] Figure 7 The particle size distribution diagram and transmission electron microscopy changes of the hybrid nanogel prepared in the present invention after incubation with 10 mM GSH for 24 hours (scale bar = 100 nm).

[0028] Figure 8 The release curves of tirapazamine entrapped in the hybrid nanogel prepared in the present invention after incubation with 10 mM GSH for different time periods.

[0029] Fig. 9 The singlet oxygen generation of the hybrid nanogel prepared in the present invention.

[0030] Fig.10 The figure shows the ROS generation of the hybrid nanogel prepared in the present invention under normoxia (21% O2).

[0031] Fig.11 The figure shows the ROS generation of the hybrid nanogel prepared in the present invention under hypoxic (1% O2) conditions.

[0032] Fig.12 The hybrid nanogel prepared in the present invention kills breast cancer cells under normoxic (21% O2) conditions.

[0033] Fig.13 The hybrid nanogel prepared in the present invention kills breast cancer cells under hypoxic (1% O2) conditions. DETAILED DESCRIPTION

[0034] The principles and features of the present invention are described below in conjunction with embodiments. The examples given are only used to explain the present invention and are not used to limit the scope of the present invention.

[0035] Example 1

[0036] Synthesis of Hydrophilic Polymer Derivative Dextrin-Protoporphyrin IX-Phenylboronic Acid (Dex-PpIX-PBA)

[0037] Step 1: 1 g of dextrin was dissolved in 10 mL of dimethyl sulfoxide solvent, and then 970 mg of dicyclohexylcarbodiimide and 180 mg of 4-dimethylaminopyridine were added.

[0038] Step 2: Add 150 mg of protoporphyrin IX and 600 mg of 4-carboxyphenylboronic acid to the solution obtained in step 1, and stir the mixture at 50° C. under nitrogen protection for 24 hours.

[0039] Step 3, add 100 mL of ice-cold ether to the mixed solution obtained in step 2, centrifuge the solvent at 5000 rpm for 10 minutes, dissolve the obtained white precipitate in 10 mL of deionized water, dialyze the solution using a dialysis bag with a MWCO of 12 kDa, and then freeze-dry to obtain the hydrophilic polymer derivative dextrin-protoporphyrin IX-phenylboronic acid.

[0040] Figure 1 This is the hydrogen nuclear magnetic resonance spectrum of the hydrophilic polymer derivative dextrin-protoporphyrin IX-phenylboronic acid (Dex-PpIX-PBA) in the present invention. Compared with the hydrogen nuclear magnetic resonance spectrum of dextrin, the extra peaks at 7.0ppm to 8.0ppm in the hydrogen nuclear magnetic resonance spectrum of Dex-PpIX-PBA belong to the porphyrin ring (marked 1 in the figure), and the extra proton peak at 10.2ppm belongs to the benzene ring (marked 2 in the figure), which proves the successful modification of protoporphyrin IX and phenylboronic acid.

[0041] Figure 2 The infrared spectrum of the hydrophilic polymer derivative dextrin-protoporphyrin IX-phenylboronic acid (Dex-PpIX-PBA) in the present invention is shown in Figure 1. Compared with dextrin, Dex-PpIX-PBA has a higher infrared spectrum at 1201 cm -1 and 677cm -1 The absorption peak at 1725 cm -1 The absorption peak at is attributed to the stretching of the benzene ring of phenylboronic acid, proving the successful modification of protoporphyrin IX and phenylboronic acid.

[0042] Figure 3 The standard curve of concentration-ultraviolet absorbance of protoporphyrin IX at 406 nm in the present invention is used to calculate the substitution degree of the sonosensitizer protoporphyrin IX in Dex-PpIX-PBA to be 26 μg / mg.

[0043] Figure 4 is the concentration-ultraviolet absorbance standard curve of phenylboronic acid at 252 nm in the present invention, and the substitution degree of phenylboronic acid in Dex-PpIX-PBA is calculated to be 34 μg / mg.

[0044] Figure 5 The singlet oxygen generation of Dex-PpIX-PBA with different degrees of protoporphyrin IX substitution prepared in the present invention. Singlet oxygen green fluorescent probe Singlet Oxygen Sensor Green (SOSG) can highly selectively bind singlet oxygen to produce green fluorescence. By comparing the ratio of the fluorescence intensity (IA) of SOSG after 3 minutes of ultrasound (1W / cm2, 1MHz) to its initial fluorescence intensity (I0), it can be seen that with the increase of protoporphyrin IX substitution, the singlet oxygen generation effect of Dex-PpIX-PBA is enhanced (13μg / mg~47μg / mg). However, due to aggregation quenching, the singlet oxygen generation ability of Dex-PpIX-PBA with a high degree of protoporphyrin IX is reduced (62μg / mg).

[0045] Example 2

[0046] Preparation of hybrid nanogels

[0047] Step 1: Mix 3.5 mg / mL potassium permanganate solution (18 mL) and 37.4 mg / mL polyallylamine solution (2 mL), and react at room temperature for 2 hours to obtain positively charged manganese dioxide nanoparticles.

[0048] Step 2, dissolve 13 μg of manganese dioxide nanoparticles obtained in step 1, 1 mg of Dex-PpIX-PBA and 100 μg of tirapazamine in a mixed solution of 5 mL of deionized water and 5 mL of ethanol, and vortex the mixed solution for 1 minute.

[0049] Step 3, dialyze the mixed solution in step 2 for 24 hours using 10 mL of a solution containing 0.01 mol of sodium dihydrogen phosphate and sodium dihydrogen phosphate.

[0050] Step 4, centrifuge the solution in the dialysis bag in step 3 at 12000 rpm for 30 minutes to remove unencapsulated manganese dioxide, use a 0.22 μm cellulose acetate filter to remove unencapsulated Dex-PpIX-PBA, and use a cellulose ultrafiltration membrane with a molecular weight cutoff of 10000 to remove unencapsulated tirapazamine.

[0051] Figure 6 The particle size distribution diagram and transmission electron microscope morphology of the hybrid nanogel (DPP / TPZ@MnO2) prepared in the present invention are shown. It can be seen that the average particle size of the prepared hybrid nanogel is about 100 nanometers. Its suitable nanometer size not only makes it convenient for intravenous injection in vivo, but also enables it to effectively accumulate in the tumor site through the EPR effect (Enhanced Permeability and Retention Effect).

[0052] Figure 7 The particle size distribution diagram and transmission electron microscopic changes of the hybrid nanogel prepared in the present invention after incubation with 10mM GSH for 24 hours show that the manganese dioxide component in the hybrid nanogel can react with the high concentration of glutathione in the tumor site to achieve rapid disintegration of the nanogel in the tumor site. In this state, the DPP in the nanogel system returns to a loose state, which can enhance the sonodynamic effect of the sonosensitizer; at the same time, the encapsulated TPZ can be quickly released to exert a synergistic anti-tumor effect.

[0053] Figure 8 The release curves of tirapazamine entrapped in the hybrid nanogel prepared in the present invention after incubation with 10 mM GSH for different time periods are shown in the figure. As can be seen from the figure, the hybrid nanogel can react with high concentration of glutathione to rapidly release the entrapped contents.

[0054] Example 3

[0055] Singlet oxygen generation in hybrid nanogels

[0056] Step 1, using singlet oxygen green fluorescent probe (SOSG) as a singlet oxygen detection probe, adding it to a nanogel containing 100 μg / ml protoporphyrin IX sonosensitizer dissolved in isotonic phosphate buffer, and then ultrasonically treated (1 W / cm2, 1 MHz) for 3 minutes. The fluorescence intensity change of SOSG (Ex = 488 nm, Em = 525 nm) was observed by a multifunctional microplate reader.

[0057] Step 2, using mouse breast cancer cells 4T1, the hybrid nanogel was used to investigate the production of reactive oxygen species in tumor cells. 4T1 cells were inoculated into 24-well plates and then cultured under normoxic conditions (21% oxygen concentration) and hypoxic conditions (1% oxygen concentration). Nanogels containing 10 μg / ml protoporphyrin IX sonosensitizer were incubated with 4T1 cells for 4 hours and then sonicated (1 W / cm 2 , 1 MHz) for 3 minutes. ROS probe was used to investigate the ROS level in 4T1 cells.

[0058] Fig. 9 The singlet oxygen generation of the hybrid nanogel prepared in the present invention is shown in the figure. As can be seen from the figure, the nanogel can generate efficient singlet oxygen under ultrasonic conditions, and the sonodynamic effect of the nanogel that disintegrates after reacting with high concentration GSH is improved.

[0059] Fig.10 The hybrid nanogel prepared in the present invention is heated in normal oxygen (21% O 2 ) Compared with liposomes loaded with protoporphyrin IX sonosensitizer, nanogels showed efficient sonodynamic therapy under normoxic conditions.

[0060] Fig.11 The hybrid nanogel prepared in the present invention is subjected to hypoxia (1% O 2 ) The ROS production under hypoxic conditions. Compared with liposomes loaded with protoporphyrin IX sonosensitizer, nanogels showed efficient sonodynamic therapy under hypoxic conditions.

[0061] Example 4

[0062] Cytotoxicity assay of hybrid nanogels

[0063] Step 1, 4T1 cells were inoculated into a 96-well plate, and then cultured under normoxic conditions (21% oxygen concentration) and hypoxic conditions (1% oxygen concentration). After the cell density increased to between 60% and 80%, hybrid nanogels of different concentrations were incubated with tumor cells for 4 hours.

[0064] In step 2, the nanogels were replaced with fresh culture medium and sonicated for 3 min (1 W / cm2, 1 MHz).

[0065] Step 3, after incubation for 24 hours, add 20 μl of 5 mg / mL thiazolyl blue and incubate for another 4 hours, then discard the supernatant and add 200 μl of DMSO, and examine the absorbance of the cells at 570 nm using a multifunctional microplate reader. Cell survival rate = (absorbance of the drug group - absorbance of the blank group) / (absorbance of the negative control group - absorbance of the blank group) * 100%.

[0066] Fig.12 The hybrid nanogel prepared in the present invention is heated in normal oxygen (21% O 2 ) conditions. As can be seen from the figure, the nanogel exhibited a good sonodynamic tumor killing effect under normoxic conditions.

[0067] Fig.13 The hybrid nanogel prepared in the present invention is subjected to hypoxia (1% O 2 ) under hypoxic conditions. As can be seen from the figure, the nanogel exhibited a good sonodynamic tumor killing effect under hypoxic conditions.

[0068] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy, characterized in that: A hydrophilic polymer derivative is used to self-assemble with manganese dioxide in an inorganic salt solution to encapsulate an oxygen-responsive drug; the hydrophilic polymer derivative is obtained by modifying phenylboronic acid and a sonosensitizer on a hydrophilic polymer material through a one-step method; the hydrophilic polymer material is selected from any one of starch, dextrin, hyaluronic acid, chitosan, dextran, gelatin or silk fibroin.

2. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to claim 1, characterized in that: The molecular weight of the hydrophilic polymer material is 10000-200000; the substitution degree of the sonosensitizer on the main chain of the hydrophilic polymer material is 20-50 μg / mg, and the substitution degree of phenylboronic acid on the main chain of the hydrophilic polymer material is 20-200 μg / mg.

3. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to claim 1, characterized in that: The macromolecular hydrophilic macromolecular material is dextrin; the sonosensitizer is protoporphyrin IX; and the phenylboric acid is 4-carboxylphenylboric acid.

4. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to claim 1, characterized in that: The inorganic salt solution is sodium dihydrogen phosphate and disodium hydrogen phosphate solution; the surface of the manganese dioxide is modified with any one of polyallylamine, polyethyleneimine or chitosan; the phenylboric acid is any one of 4-aminophenylboric acid, 3-aminophenylboric acid, o-aminophenylboric acid, 4-carboxyphenylboric acid, 3-carboxyphenylboric acid or 2-carboxyphenylboric acid.

5. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to claim 4, characterized in that: The surface modified manganese dioxide has a positive potential and a size of 10-40 nanometers.

6. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to claim 1, characterized in that: The hypoxia responsive drug is one of tirapazamine, apaziquinone, ivophosphamide, banothramine and tasotinib.

7. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to claim 1, characterized in that: The phenylboronic acid and sonosensitizer are obtained by modifying the hydrophilic polymer material through a one-step method, specifically: the hydrophilic polymer material is dissolved in a dimethyl sulfoxide solvent, then dicyclohexylcarbodiimide and 4-dimethylaminopyridine are added to obtain a hydrophilic polymer material solution, the mixture of phenylboronic acid and sonosensitizer is stirred at 40-55° C. under nitrogen protection to obtain a mixed solution, the mixed solution is added into ice-cold ether, centrifuged, a white precipitate is obtained, dissolved in deionized water, dialyzed using a dialysis bag, and freeze-dried.

8. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to claim 7, characterized in that: The molecular weight of the selected dialysis bag is 10,000 to 100,000 molecular weight, and the concentration of the dialysate is 0.01 molar.

9. The method for preparing a hybrid nanogel for enhancing tumor sonodynamic therapy according to any one of claims 1 to 8, characterized in that: The mass ratio of the hydrophilic polymer material to manganese dioxide is 100:0.5-10, and the concentration of the hypoxia-responsive drug is 100 μg / mL.

10. Use of the hybrid nanogel obtained by the method for preparing the hybrid nanogel for enhancing tumor sonodynamic therapy according to any one of claims 1 to 9 in preparing therapeutic drugs for tumors or hypoxic tumor-related diseases.

Citation Information

Patent Citations

  • CO gas synergistic chemical-dynamic therapy anti-tumor nano delivery carrier, preparation method and application in anti-tumor drugs

    CN111388450A

  • Preparation method and anti-tumor application of manganese dioxide nanosheet hybrid hydrogel

    CN111671899A

  • Preparation for enhancing hypoxic tumor photodynamic therapy and preparation method and application of preparation

    CN112618727A

  • Inorganic sound-sensitive agent independent of oxygen in tumor microenvironment as well as preparation method and application of inorganic sound-sensitive agent

    CN114246947A

  • Manganese-based composite hydrogel as well as preparation method and application thereof

    CN116725942A